POMALIDOMIDE/STADA
FORM
Hard capsules
STRENGTH
1,2,3,4mg
INDICATIONS
- Pomalidomide/STADA in combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have previously received at least one treatment regimen, including an immunomodulatory agent such as lenalidomide.
- Pomalidomide/STADA in combination with dexamethasone is indicated for adult patients with relapsed or refractory multiple myeloma after at least two prior therapies that included lenalidomide and bortezomib, and with documented disease progression.
Important note
This medicinal product should be prescribed by an appropriate healthcare professional.
